Hydrocodone Bitartrate
FDA-approved product (capsule, extended release, oral), marketed as Hydrocodone Bitartrate, Hysingla Er, Vantrela Er and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cough
- Drug dependence
- Pain
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Natural opium alkaloids; Opium alkaloids and derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA44.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis36.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Hydrocodone Bitartrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
NSAIDS Versus Opioids in Acute SER II Ankle Fractures
NCT02373254 · start 2015-01
Registered record
- Registry ID
- NCT02373254
- Conditions
- Ankle Fracture
- Interventions
- Ibuprofen; Acetaminophen/hydrocodone
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Completed
- Start
- 2015-01
- Completion
- 2015-10
- Enrolment
- 1
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnkle FractureInterventionIbuprofen; Acetaminophen/hydrocodonePhaseEarly phase 1Registry statusCompletedA Randomized, Open Label, Prospective Study to Explore the Clinical Characteristics of Oral MNK155 and Norco 7.5mg/325 When Used for the Treatment of Moderate to Severe Post Operative Pain
NCT02381132 · start 2014-11
Registered record
- Registry ID
- NCT02381132
- Conditions
- Post Operative Pain
- Interventions
- Norco 7.5mg/325; MNK155
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2014-11
- Completion
- 2015-12
- Enrolment
- 99
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPost Operative PainInterventionNorco 7.5mg/325; MNK155PhasePhase 3Registry statusTerminatedPeripheral Nerve Blocks in Pediatric Orthopedic Patients
NCT02236130 · start 2014-06
Registered record
- Registry ID
- NCT02236130
- Conditions
- Pediatric Extremity Fracture; Pediatric Extremity Soft Tissue Injury
- Interventions
- Regional block; General Anesthesia; Local Anesthetic Ropivacaine; Opioids Morphine; Oral pain medication Acetaminophen with Hydrocodone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Terminated
- Start
- 2014-06
- Completion
- 2015-10
- Enrolment
- 49
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPediatric Extremity Fracture; Pediatric Extremity Soft Tissue InjuryInterventionRegional block; General Anesthesia; Local Anesthetic Ropivacaine; Opioids Morphine +1 morePhaseNot applicableRegistry statusTerminatedPhase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain
NCT01780428 · start 2013-01
Registered record
- Registry ID
- NCT01780428
- Conditions
- Pain; Nausea; Vomiting
- Interventions
- CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2013-01
- Completion
- 2014-12
- Enrolment
- 460
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPain; Nausea; VomitingInterventionCL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg); PlaceboPhasePhase 3Registry statusCompletedA Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet
NCT01758978 · start 2012-12
Registered record
- Registry ID
- NCT01758978
- Conditions
- Pain
- Interventions
- a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-12
- Completion
- 2013-01
- Enrolment
- 54
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventiona 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).PhasePhase 1Registry statusCompletedStudy of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery
NCT01592708 · start 2012-06
Registered record
- Registry ID
- NCT01592708
- Conditions
- Post-operative Nausea; Post-operative Vomiting; Nausea Persistent
- Interventions
- Antiemetic anesthesia protocol
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2012-06
- Completion
- 2014-04
- Enrolment
- 233
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPost-operative Nausea; Post-operative Vomiting; Nausea PersistentInterventionAntiemetic anesthesia protocolPhaseNot applicableRegistry statusCompletedComparing the Efficacy of Oral Opioids for Outpatient Acute Pain Management After ED Discharge Discharge
NCT01402375 · start 2012-01
Registered record
- Registry ID
- NCT01402375
- Conditions
- Analgesia After ED Discharge for Extremity Injuries
- Interventions
- Hydrocodone (first trial); Codeine (first trial); Oxycodone (for second trial); Codeine (for second trial); Oxycodone (third trial); Hydrocodone (third trial)
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-01
- Completion
- 2014-11
- Enrolment
- 720
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnalgesia After ED Discharge for Extremity InjuriesInterventionHydrocodone (first trial); Codeine (first trial); Oxycodone (for second trial); Codeine (for second trial) +2 morePhasePhase 3Registry statusCompletedPharmacokinetics and Bioequivalence of Vycavert (10 mg Hydrocodone Bitartrate/325 mg Acetaminophen) Compared to the Reference Drug Norco
NCT01456520 · start 2011-10
Registered record
- Registry ID
- NCT01456520
- Conditions
- Healthy
- Interventions
- Vycavert; Norco
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-10
- Completion
- 2012-01
- Enrolment
- 47
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionVycavert; NorcoPhasePhase 1Registry statusCompletedLong-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.
NCT01400139 · start 2011-07
Registered record
- Registry ID
- NCT01400139
- Conditions
- Chronic Nonmalignant and Nonneuropathic Pain
- Interventions
- Hydrocodone bitartrate q24h film-coated tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-07
- Completion
- 2013-10
- Enrolment
- 922
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Nonmalignant and Nonneuropathic PainInterventionHydrocodone bitartrate q24h film-coated tabletsPhasePhase 3Registry statusCompletedA Study to Evaluate the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Hepatic Function and Subjects With Moderate Hepatic Impairment
NCT01319279 · start 2011-04
Registered record
- Registry ID
- NCT01319279
- Conditions
- Hepatic Impairment
- Interventions
- Hydrocodone bitartrate extended-release tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-04
- Completion
- 2011-08
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatic ImpairmentInterventionHydrocodone bitartrate extended-release tabletPhasePhase 1Registry statusCompletedPharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment
NCT02242734 · start 2011-02
Registered record
- Registry ID
- NCT02242734
- Conditions
- Hepatic Impairment
- Interventions
- 20 mg HC-ER; 20 mg HC-ER; 20 mg HC-ER
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-02
- Completion
- 2011-05
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHepatic ImpairmentIntervention20 mg HC-ER; 20 mg HC-ER; 20 mg HC-ERPhasePhase 1Registry statusCompletedPhase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain
NCT01081912 · start 2010-03
Registered record
- Registry ID
- NCT01081912
- Conditions
- Back Pain Lower Back Chronic
- Interventions
- Placebo; Hydrocodone bitartrate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-03
- Completion
- 2011-10
- Enrolment
- 510
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBack Pain Lower Back ChronicInterventionPlacebo; Hydrocodone bitartratePhasePhase 3Registry statusCompletedHydrocodone/Acetaminophen for Acute Pain Following Bunionectomy
NCT01038609 · start 2009-12
Registered record
- Registry ID
- NCT01038609
- Conditions
- Pain
- Interventions
- Hydrocodone/Acetaminophen Extended Release; Acetaminophen; Morphine Extended Release; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-12
- Completion
- 2010-05
- Enrolment
- 250
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionHydrocodone/Acetaminophen Extended Release; Acetaminophen; Morphine Extended Release; PlaceboPhasePhase 2Registry statusCompletedA Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)
NCT02126917 · start 2009-11
Registered record
- Registry ID
- NCT02126917
- Conditions
- Healthy
- Interventions
- HC-ER + 40% Alcohol; HC-ER + 20% Alcohol; HC-ER + 0% Alcohol
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-11
- Completion
- 2009-12
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionHC-ER + 40% Alcohol; HC-ER + 20% Alcohol; HC-ER + 0% AlcoholPhasePhase 1Registry statusCompletedThe Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache
NCT00574015 · start 2007-12
Registered record
- Registry ID
- NCT00574015
- Conditions
- Toothache
- Interventions
- hydrocodone/acetaminophen; bupivacaine (supraperiosteal nerve block)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2007-12
- Completion
- 2013-01
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionToothacheInterventionhydrocodone/acetaminophen; bupivacaine (supraperiosteal nerve block)PhasePhase 4Registry statusCompleted